Neon Therapeutics (NASDAQ:NTGN) had its price target lifted by HC Wainwright from $10.00 to $12.00 in a research report sent to investors on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 target price on the stock in a research report on Tuesday. Mizuho set a $21.00 target price on shares of Neon Therapeutics and gave the stock a buy rating in a research report on Monday, July 1st. Finally, Berenberg Bank decreased their target price on shares of Lucara Diamond from C$1.60 to C$1.50 in a research report on Wednesday, March 27th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $16.00.
NASDAQ:NTGN traded down $0.40 during trading hours on Tuesday, reaching $3.73. The company’s stock had a trading volume of 6,821 shares, compared to its average volume of 193,300. The company has a market capitalization of $122.39 million and a price-to-earnings ratio of -0.66. The firm’s 50-day moving average price is $4.70. Neon Therapeutics has a 1 year low of $4.08 and a 1 year high of $13.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.30 and a quick ratio of 7.30.
Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Neon Therapeutics by 1.1% in the fourth quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the period. BlackRock Inc. increased its position in shares of Neon Therapeutics by 12.0% in the fourth quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock valued at $1,548,000 after acquiring an additional 32,943 shares during the period. Northern Trust Corp increased its position in shares of Neon Therapeutics by 68.9% in the fourth quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock valued at $446,000 after acquiring an additional 36,170 shares during the period. Geode Capital Management LLC increased its position in shares of Neon Therapeutics by 127.0% in the fourth quarter. Geode Capital Management LLC now owns 60,309 shares of the company’s stock valued at $303,000 after acquiring an additional 33,741 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of Neon Therapeutics in the first quarter valued at about $268,000. Hedge funds and other institutional investors own 69.57% of the company’s stock.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.